4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity
P. Ind, J. Haughney, D. Price, J. P. Rosen, J. Kennelly (London, Luton, United Kingdom)
Source: Annual Congress 2002 - Asthma - Therapy and management -1
Session: Asthma - Therapy and management -1
Session type: Thematic Poster Session
Number: 378
Disease area: Airway diseases
Abstract AIM(S):The Symbicort Adjustable Maintenance Plan is designed to gain and maintain optimal asthma control with a lower overall dose of budesonide/formoterol (B/F; Symbicort® Turbuhaler®) than fixed dosing. METHODS:Patients (mean age 48 y) were randomised to adjustable maintenance (n=782; B/F 2 inhalations bid for 4 weeks, thereafter 1–4 inh bid depending on symptoms for 12 weeks) or fixed B/F dosing (n=771; 2 inh bid for 16 weeks). Primary efficacy variables were reduction in symptom severity (according to GINA definitions) and total exacerbations. RESULTS: Changes in symptom severity are shown below:
Symptom severity Screening (week 0) Baseline (week 4) Endpoint (week 16 or time of withdrawal) A* F** A F A F No. patients 775 766 775 766 754 737 Severity status (%) Severe persistent 6 6 4 4 4 4 Moderate persistent 45 47 34 33 25 25 Mild persistent 31 29 32 31 31 30 Mild intermittent 18 19 30 33 40 40
*A=adjustable; **F=fixed. 94% of patients (both groups) reported no exacerbations. The average number of inhalations was 15% lower in the adjustable group. CONCLUSIONS:Patients treated with both adjustable and fixed-dose B/F combination demonstrated a reduction in symptom severity. Overall there was a 46% reduction in patients graded as moderate persistent and a doubling of patients categorised as mild intermittent. A reduced overall daily dose was observed in the adjustable arm.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Ind, J. Haughney, D. Price, J. P. Rosen, J. Kennelly (London, Luton, United Kingdom). 4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity. Eur Respir J 2002; 20: Suppl. 38, 378
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018
Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
The ATACO study: adjustable maintenance therapy with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002
Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002